These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32824226)

  • 1. Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
    Wakasaki T; Yasumatsu R; Masuda M; Takeuchi T; Manako T; Matsuo M; Jiromaru R; Uchi R; Komune N; Noda T; Nakagawa T
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck.
    Reverdy T; Varnier R; de Talhouët S; Duplomb S; Bruyas A
    Oral Oncol; 2023 Oct; 145():106533. PubMed ID: 37562096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
    Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.
    Wakasaki T; Manako T; Yasumatsu R; Hara H; Toh S; Masuda M; Yamauchi M; Kuratomi Y; Nishimura E; Takeuchi T; Matsuo M; Jiromaru R; Hashimoto K; Komune N; Nakagawa T
    PLoS One; 2022; 17(7):e0271907. PubMed ID: 35901098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma.
    Fushimi C; Okamoto I; Matsuki T; Masubuchi T; Okada T; Sato H; Tsukahara K; Kondo T; Yamashita T; Hanyu K; Omura GO; Takahashi H; Tada Y; Miura K
    Anticancer Res; 2020 Sep; 40(9):5277-5283. PubMed ID: 32878817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of programmed death-ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma.
    Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
    Head Neck; 2020 Nov; 42(11):3275-3281. PubMed ID: 32671898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors.
    Sakai A; Ebisumoto K; Iijima H; Yamauchi M; Teramura T; Yamazaki A; Watanabe T; Inagi T; Maki D; Okami K
    Discov Oncol; 2023 Aug; 14(1):158. PubMed ID: 37642856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients.
    Matsuki T; Okamoto I; Fushimi C; Sawabe M; Kawakita D; Sato H; Tsukahara K; Kondo T; Okada T; Tada Y; Miura K; Omura G; Yamashita T
    Cancer Med; 2020 Jul; 9(14):5015-5024. PubMed ID: 32441463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab.
    Haas M; Lein A; Fuereder T; Schnoell J; Brkic FF; Liu DT; Kadletz-Wanke L; Heiduschka G; Jank BJ
    Invest New Drugs; 2023 Oct; 41(5):727-736. PubMed ID: 37603206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score.
    Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
    Eur Arch Otorhinolaryngol; 2020 Aug; 277(8):2341-2347. PubMed ID: 32239313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
    Zargar M; McFarlane T; Chan KKW; Wong WWL
    Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.
    Lala M; Chirovsky D; Cheng JD; Mayawala K
    Oral Oncol; 2018 Sep; 84():108-120. PubMed ID: 30115469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer.
    Yasumatsu R; Wakasaki T; Hashimoto K; Nakashima K; Manako T; Taura M; Matsuo M; Nakagawa T
    Head Neck; 2019 Aug; 41(8):2610-2618. PubMed ID: 30835919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neutrophil to lymphocyte ratio in peripheral blood: a novel independent prognostic factor in patients with head and neck squamous cell carcinoma].
    Wu F; Wu LL; Zhu LX
    Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):29-32. PubMed ID: 28104030
    [No Abstract]   [Full Text] [Related]  

  • 16. [Neutrophil-to-Lymphocyte Ratio(NLR)as a Predictive Indicator of the Response to Nivolumab in Patients with Oral Squamous Cell Carcinoma].
    Tachinami H; Tomihara K; Ikeda A; Sekido K; Sakurai K; Imaue S; Fujiwara K; Hayashi R; Noguchi M
    Gan To Kagaku Ryoho; 2021 Dec; 48(12):1485-1490. PubMed ID: 34911916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of peripheral lymphocyte counts for immune checkpoint inhibitor efficacy in advanced head and neck squamous cell carcinoma.
    Park JC; Durbeck J; Clark JR
    Mol Clin Oncol; 2020 Dec; 13(6):87. PubMed ID: 33194194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
    Soda H; Ogawara D; Fukuda Y; Tomono H; Okuno D; Koga S; Taniguchi H; Yoshida M; Harada T; Umemura A; Yamaguchi H; Mukae H
    Thorac Cancer; 2019 Feb; 10(2):341-346. PubMed ID: 30582295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma.
    Ishihara H; Tachibana H; Takagi T; Kondo T; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Target Oncol; 2019 Aug; 14(4):453-463. PubMed ID: 31359231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
    Suzuki S; Abe T; Endo T; Kaya H; Kitabayashi T; Kawasaki Y; Yamada T
    Cancer Manag Res; 2022; 14():3293-3302. PubMed ID: 36452436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.